Calmangafodipir

Unassigned

New Medicines

PledOx · Neuropathic pain secondary to chemotherapy treatment

Information

PledOx
New molecular entity
PledPharma
PledPharma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Antioxidant, Iron chelating agent
The prevalence of neuropathic pain has been estimated to be between 6-9%. [2]
Neuropathic pain secondary to chemotherapy treatment
Intravenous